Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Inflammation
Published in: Inflammation 4/2018

01-08-2018 | ORIGINAL ARTICLE

β4GalT1 Mediates PPARγ N-Glycosylation to Attenuate Microglia Inflammatory Activation

Authors: Xiaojuan Liu, Aihong Li, Yuanyuan Ju, Wangrui Liu, Hui Shi, Renyue Hu, Zijian Zhou, Xiaolei Sun

Published in: Inflammation | Issue 4/2018

Login to get access

Abstract

The inflammatory activation of microglia has double-edged effects in central nervous system (CNS) diseases. The ligand-activated transcriptional factor peroxisome proliferator-activated receptor γ (PPARγ) inhibits the inflammatory response. β-1,4-Galactosyltransferase Ι (β1, 4GalT1) mediates N-glycosylation. In this study, the N-glycosylation of PPARγ, as well as two N-linked glycosylation sites in its DNA binding domain (DBD), was identified. Disruption of both sites by site-directed mutagenesis completely abrogated the N-glycosylation of PPARγ. PPAR wild-type (WT) transfection inhibited the inflammatory activation of microglia, while the anti-inflammatory function of unglycosylated PPARγ was down-regulated. In addition, β1, 4GalT1 was shown to interact with PPARγ and to mediate PPARγ glycosylation. β1, 4GalT1 promoted PPARγ’s anti-transcription and anti-inflammatory functions. Collectively, our findings define that β-1, 4GalT1 mediated PPARγ glycosylation to attenuate the inflammatory activation of microglia, which has implications for potential therapies for CNS inflammatory diseases.
Literature
1.
2.
Wang Y, Ruan W, Mi J, Xu J, Wang H, Cao Z, et al. Balasubramide derivative 3C modulates microglia activation via CaMKKbeta-dependent AMPK/PGC-1alpha pathway in neuroinflammatory conditions. Brain, Behavior, and Immunity 2017.
3.
Lim H, Lee H, Noh K, Lee SJ. IKK/NF-kappa B-Dependent satellite glia activation induces spinal cord microglia activation and neuropathic pain after nerve injury. Pain 2017; 158:1666–1677.
4.
Kaminska B, Mota M, Pizzi M. Signal transduction and epigenetic mechanisms in the control of microglia activation during neuroinflammation. Biochimica et Biophysica Acta 2016; 1862:339–351.
5.
Arafah, K., D. Croix, J. Vizioli, A. Desmons, I. Fournier, and M. Salzet. 2013. Involvement of nitric oxide through endocannabinoids release in microglia activation during the course of CNS regeneration in the medicinal leech. Glia 61: 636–649.CrossRefPubMed
6.
Villapol S. Roles of peroxisome proliferator-activated receptor gamma on brain and peripheral inflammation. Cellular and Molecular Neurobiology 2017.
7.
Narala, V.R., P.A. Subramani, V.R. Narasimha, F.B. Shaik, and K. Panati. 2014. The role of nitrated fatty acids and peroxisome proliferator-activated receptor gamma in modulating inflammation. International Immunopharmacology 23: 283–287.CrossRefPubMed
8.
Martin, H. 2010. Role of PPAR-gamma in inflammation. Prospects for therapeutic intervention by food components. Mutation Research 690: 57–63.CrossRefPubMed
9.
10.
Han T, Liu M, Yang S. DJ-1 alleviates angiotensin II-induced endothelial progenitor cell damage by activating the PPARgamma/HO-1 pathway. Journal of Cellular Biochemistry 2017.
11.
Cai, W., T. Yang, H. Liu, L. Han, K. Zhang, X. Hu, X. Zhang, K.J. Yin, Y. Gao, M.V.L. Bennett, R.K. Leak, and J. Chen. 2017. Peroxisome proliferator-activated receptor gamma (PPARgamma): A master gatekeeper in CNS injury and repair. Progress in Neurobiology.
12.
Pu, Y., and A. Veiga-Lopez. 2017. PPARgamma agonist through the terminal differentiation phase is essential for adipogenic differentiation of fetal ovine preadipocytes. Cellular & Molecular Biology Letters 22: 6.CrossRef
13.
Kim, J.C. 2016. The effect of exercise training combined with PPARgamma agonist on skeletal muscle glucose uptake and insulin sensitivity in induced diabetic obese Zucker rats. J Exerc Nutrition Biochem 20: 42–50.CrossRefPubMedPubMedCentral
14.
Tol, M.J., R. Ottenhoff, M. van Eijk, N. Zelcer, J. Aten, S.M. Houten, D. Geerts, C. van Roomen, M.C. Bierlaagh, S. Scheij, M.A. Hoeksema, J.M. Aerts, J.S. Bogan, G.W. Dorn 2nd, C.A. Argmann, and A.J. Verhoeven. 2016. A PPARgamma-Bnip3 Axis couples adipose mitochondrial fusion-fission balance to systemic insulin sensitivity. Diabetes 65: 2591–2605.CrossRefPubMedPubMedCentral
15.
Pawlak, M., P. Lefebvre, and B. Staels. 2015. Molecular mechanism of PPARalpha action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease. Journal of Hepatology 62: 720–733.CrossRefPubMed
16.
Merlin, J., M. Sato, C. Nowell, M. Pakzad, R. Fahey, J. Gao, et al. 2017. The PPARgamma agonist rosiglitazone promotes the induction of brite adipocytes, increasing beta-adrenoceptor-mediated mitochondrial function and glucose uptake. Cellular Signalling 42: 54–66.CrossRefPubMed
17.
Niu, Z., Q. Shi, W. Zhang, Y. Shu, N. Yang, B. Chen, Q. Wang, X. Zhao, J. Chen, N. Cheng, X. Feng, Z. Hua, J. Ji, and P. Shen. 2017. Caspase-1 cleaves PPARgamma for potentiating the pro-tumor action of TAMs. Nature Communications 8: 766.CrossRefPubMedPubMedCentral
18.
Ricote, M., J. Huang, L. Fajas, A. Li, J. Welch, J. Najib, J.L. Witztum, J. Auwerx, W. Palinski, and C.K. Glass. 1998. Expression of the peroxisome proliferator-activated receptor gamma (PPARgamma) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein. Proceedings of the National Academy of Sciences of the United States of America 95: 7614–7619.CrossRefPubMedPubMedCentral
19.
Hsu, W.J., N.C. Wildburger, S.J. Haidacher, M.N. Nenov, O. Folorunso, A.K. Singh, et al. 2017. PPARgamma agonists rescue increased phosphorylation of FGF14 at S226 in the Tg2576 mouse model of Alzheimer's disease. Experimental Neurology 295: 1–17.CrossRefPubMedPubMedCentral
20.
Hennet, T. 2002. The galactosyltransferase family. Cellular and Molecular Life Sciences 59: 1081–1095.CrossRefPubMed
21.
Asano, M., S. Nakae, N. Kotani, N. Shirafuji, A. Nambu, N. Hashimoto, H. Kawashima, M. Hirose, M. Miyasaka, S. Takasaki, and Y. Iwakura. 2003. Impaired selectin-ligand biosynthesis and reduced inflammatory responses in beta-1,4-galactosyltransferase-I-deficient mice. Blood 102: 1678–1685.CrossRefPubMed
22.
Guo, S., T. Sato, K. Shirane, and K. Furukawa. 2001. Galactosylation of N-linked oligosaccharides by human beta-1,4-galactosyltransferases I, II, III, IV, V, and VI expressed in Sf-9 cells. Glycobiology 11: 813–820.CrossRefPubMed
23.
Ujita, M., A.K. Misra, J. McAuliffe, O. Hindsgaul, and M. Fukuda. 2000. Poly-N-acetyllactosamine extension in N-glycans and core 2- and core 4-branched O-glycans is differentially controlled by i-extension enzyme and different members of the beta 1,4-galactosyltransferase gene family. The Journal of Biological Chemistry 275: 15868–15875.CrossRefPubMed
24.
Quentin, E., A. Gladen, L. Roden, and H. Kresse. 1990. A genetic defect in the biosynthesis of dermatan sulfate proteoglycan: Galactosyltransferase I deficiency in fibroblasts from a patient with a progeroid syndrome. Proceedings of the National Academy of Sciences of the United States of America 87: 1342–1346.CrossRefPubMedPubMedCentral
25.
Nishie, T., Y. Hikimochi, K. Zama, Y. Fukusumi, M. Ito, H. Yokoyama, C. Naruse, M. Ito, and M. Asano. 2010. Beta4-galactosyltransferase-5 is a lactosylceramide synthase essential for mouse extra-embryonic development. Glycobiology 20: 1311–1322.CrossRefPubMed
26.
Tokuda, N., S. Numata, X. Li, T. Nomura, and M. Takizawa. 2013. Kondo Y, et al. beta4GalT6 is involved in the synthesis of lactosylceramide with less intensity than beta4GalT5. Glycobiology 23: 1175–1183.CrossRefPubMed
27.
Zhang, Z.N., L. Gong, S. Lv, J. Li, X. Tai, W. Cao, B. Peng, S. Qu, W. Li, C. Zhang, and B. Luan. 2016. SIK2 regulates fasting-induced PPARalpha activity and ketogenesis through p300. Scientific Reports 6: 23317.CrossRefPubMedPubMedCentral
28.
Giulian, D., and T.J. Baker. 1986. Characterization of ameboid microglia isolated from developing mammalian brain. The Journal of Neuroscience 6: 2163–2178.CrossRefPubMedPubMedCentral
29.
Ruan, J., Z. Qi, L. Shen, Y. Jiang, Y. Xu, L. Lan, L. Luo, and Z. Yin. 2015. Crosstalk between JNK and NF-kappaB signaling pathways via HSP27 phosphorylation in HepG2 cells. Biochemical and Biophysical Research Communications 456: 122–128.CrossRefPubMed
30.
31.
Ahmadian, M., J.M. Suh, N. Hah, C. Liddle, A.R. Atkins, M. Downes, and R.M. Evans. 2013. PPARgamma signaling and metabolism: The good, the bad and the future. Nature Medicine 19: 557–566.CrossRefPubMed
32.
Bojarova, P., R.R. Rosencrantz, L. Elling, and V. Kren. 2013. Enzymatic glycosylation of multivalent scaffolds. Chemical Society Reviews 42: 4774–4797.CrossRefPubMed
33.
Dall'Olio, F., V. Vanhooren, C.C. Chen, P.E. Slagboom, M. Wuhrer, and C. Franceschi. 2013. N-glycomic biomarkers of biological aging and longevity: A link with inflammaging. Ageing Research Reviews 12: 685–698.CrossRefPubMed
34.
Javed, H., S. Azimullah, S.B. Abul Khair, S. Ojha, and M.E. Haque. 2016. Neuroprotective effect of nerolidol against neuroinflammation and oxidative stress induced by rotenone. BMC Neuroscience 17: 58.CrossRefPubMedPubMedCentral
35.
Cao, Q., A. Karthikeyan, S.T. Dheen, C. Kaur, and E.A. Ling. 2017. Production of proinflammatory mediators in activated microglia is synergistically regulated by Notch-1, glycogen synthase kinase (GSK-3beta) and NF-kappaB/p65 signalling. PLoS One 12: e0186764.CrossRefPubMedPubMedCentral
36.
Crosby, M.B., J. Svenson, G.S. Gilkeson, and T.K. Nowling. 2005. A novel PPAR response element in the murine iNOS promoter. Molecular Immunology 42: 1303–1310.CrossRefPubMed
37.
Fujimoto, Y., T. Shiraki, Y. Horiuchi, T. Waku, A. Shigenaga, A. Otaka, T. Ikura, K. Igarashi, S. Aimoto, S.I. Tate, and K. Morikawa. 2010. Proline cis/trans-isomerase Pin1 regulates peroxisome proliferator-activated receptor gamma activity through the direct binding to the activation function-1 domain. The Journal of Biological Chemistry 285: 3126–3132.CrossRefPubMed
38.
Diezko, R., and G. Suske. 2013. Ligand binding reduces SUMOylation of the peroxisome proliferator-activated receptor gamma (PPARgamma) activation function 1 (AF1) domain. PLoS One 8: e66947.CrossRefPubMedPubMedCentral
39.
Kliewer, S.A., K. Umesono, D.J. Noonan, R.A. Heyman, and R.M. Evans. 1992. Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors. Nature 358: 771–774.CrossRefPubMedPubMedCentral
40.
Juge-Aubry, C., A. Pernin, T. Favez, A.G. Burger, W. Wahli, C.A. Meier, and B. Desvergne. 1997. DNA binding properties of peroxisome proliferator-activated receptor subtypes on various natural peroxisome proliferator response elements. Importance of the 5′-flanking region. The Journal of Biological Chemistry 272: 25252–25259.CrossRefPubMed
41.
Zhang, L., M. Zhu, M. Li, Y. Du, S. Duan, Y. Huang, et al. 2017. Ginsenoside Rg1 attenuates adjuvant-induced arthritis in rats via modulation of PPAR-gamma/NF-kappaB signal pathway. Oncotarget 8: 55384–55393.PubMedPubMedCentral
42.
Kim, J.S., Y.H. Lee, Y.U. Chang, and H.K. Yi. 2017. PPARgamma regulates inflammatory reaction by inhibiting the MAPK/NF-kappaB pathway in C2C12 skeletal muscle cells. Journal of Physiology and Biochemistry 73: 49–57.CrossRefPubMed
43.
Huang, D., Q. Zhao, H. Liu, Y. Guo, and H. Xu. 2016. PPAR-alpha agonist WY-14643 inhibits LPS-induced inflammation in synovial fibroblasts via NF-kB pathway. Journal of Molecular Neuroscience 59: 544–553.CrossRefPubMed
44.
Assuncao, L.S., K.G. Magalhaes, A.B. Carneiro, R. Molinaro, P.E. Almeida, G.C. Atella, et al. 2017. Schistosomal-derived lysophosphatidylcholine triggers M2 polarization of macrophages through PPARgamma dependent mechanisms. Biochimica et Biophysica Acta 1862: 246–254.CrossRefPubMed
45.
Bouhlel, M.A., B. Derudas, E. Rigamonti, R. Dievart, J. Brozek, S. Haulon, et al. 2007. PPARgamma activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties. Cell Metabolism 6: 137–143.CrossRefPubMed
46.
Carta, A.R., and A. Pisanu. 2013. Modulating microglia activity with PPAR-gamma agonists: A promising therapy for Parkinson's disease? Neurotoxicity Research 23: 112–123.CrossRefPubMed
47.
Rai, A., S. Tripathi, R. Kushwaha, P. Singh, P. Srivastava, S. Sanyal, and S. Bandyopadhyay. 2014. CDK5-induced p-PPARgamma(Ser 112) downregulates GFAP via PPREs in developing rat brain: Effect of metal mixture and troglitazone in astrocytes. Cell Death & Disease 5: e1033.CrossRef
48.
Zhang, Y., C. Chen, Y. Jiang, S. Wang, X. Wu, and K. Wang. 2017. PPARgamma coactivator-1alpha (PGC-1alpha) protects neuroblastoma cells against amyloid-beta (Abeta) induced cell death and neuroinflammation via NF-kappaB pathway. BMC Neuroscience 18: 69.CrossRefPubMedPubMedCentral
49.
Choi, M.J., E.J. Lee, J.S. Park, S.N. Kim, E.M. Park, and H.S. Kim. 2017. Anti-inflammatory mechanism of galangin in lipopolysaccharide-stimulated microglia: Critical role of PPAR-gamma signaling pathway. Biochemical Pharmacology 144: 120–131.CrossRefPubMed
50.
Han, Q., Q. Yuan, X. Meng, J. Huo, Y. Bao, and G. Xie. 2017. 6-Shogaol attenuates LPS-induced inflammation in BV2 microglia cells by activating PPAR-gamma. Oncotarget 8: 42001–42006.PubMedPubMedCentral
51.
Ji, H., H. Wang, F. Zhang, X. Li, L. Xiang, and S. Aiguo. 2010. PPARgamma agonist pioglitazone inhibits microglia inflammation by blocking p38 mitogen-activated protein kinase signaling pathways. Inflammation Research 59: 921–929.CrossRefPubMed
52.
Chacko, B.K., D.W. Scott, R.T. Chandler, and R.P. Patel. 2011. Endothelial surface N-glycans mediate monocyte adhesion and are targets for anti-inflammatory effects of peroxisome proliferator-activated receptor gamma ligands. The Journal of Biological Chemistry 286: 38738–38747.CrossRefPubMedPubMedCentral
53.
Green, R.S., E.L. Stone, M. Tenno, E. Lehtonen, M.G. Farquhar, and J.D. Marth. 2007. Mammalian N-glycan branching protects against innate immune self-recognition and inflammation in autoimmune disease pathogenesis. Immunity 27: 308–320.CrossRefPubMed
54.
Seet, B.T., I. Dikic, M.M. Zhou, and T. Pawson. 2006. Reading protein modifications with interaction domains. Nature Reviews Molecular Cell Biology 7: 473–483.CrossRefPubMed
55.
Jackson, S.P., and R. Tjian. 1988. O-glycosylation of eukaryotic transcription factors: Implications for mechanisms of transcriptional regulation. Cell 55: 125–133.CrossRefPubMed
56.
Gewinner, C., G. Hart, N. Zachara, R. Cole, C. Beisenherz-Huss, and B. Groner. 2004. The coactivator of transcription CREB-binding protein interacts preferentially with the glycosylated form of Stat5. The Journal of Biological Chemistry 279: 3563–3572.CrossRefPubMed
57.
Ahmad, I., D.C. Hoessli, E. Walker-Nasir, M.I. Choudhary, S.M. Rafik, A.R. Shakoori, and Nasir-ud-Din. 2006. Phosphorylation and glycosylation interplay: Protein modifications at hydroxy amino acids and prediction of signaling functions of the human beta3 integrin family. Journal of Cellular Biochemistry 99: 706–718.CrossRefPubMed
58.
Chan, C.P., T.Y. Mak, K.T. Chin, I.O. Ng, and D.Y. Jin. 2010. N-linked glycosylation is required for optimal proteolytic activation of membrane-bound transcription factor CREB-H. Journal of Cell Science 123: 1438–1448.CrossRefPubMed
59.
Molyneux, K., D. Wimbury, I. Pawluczyk, M. Muto, and J. Bhachu. 2017. Mertens PR, et al. beta1,4-galactosyltransferase 1 is a novel receptor for IgA in human mesangial cells. Kidney International 92: 1458–1468.CrossRefPubMed
60.
Mori, R., T. Kondo, T. Nishie, T. Ohshima, and M. Asano. 2004. Impairment of skin wound healing in beta-1,4-galactosyltransferase-deficient mice with reduced leukocyte recruitment. The American Journal of Pathology 164: 1303–1314.CrossRefPubMedPubMedCentral
61.
Hu, L., H. Yang, J. Chen, X. Li, Z. Ben, X. He, et al. 2011. beta-1,4-galactosyltransferase-involved in lipopolysaccharide-induced adhesion of Schwann cells. Inflammation Research 60: 169–174.CrossRefPubMed
62.
Liu, X., C. Cheng, B. Shao, X. Wu, Y. Ji, X. Lu, and A. Shen. 2012. The functional interaction between CDK11p58 and beta-1,4-galactosyltransferase I involved in astrocyte activation caused by lipopolysaccharide. Inflammation 35: 1365–1377.CrossRefPubMed
63.
64.
Tang, W., S. Weng, S. Zhang, W. Wu, L. Dong, X. Shen, S. Zhang, J. Gu, and R. Xue. 2013. Direct interaction between surface beta1,4-galactosyltransferase 1 and epidermal growth factor receptor (EGFR) inhibits EGFR activation in hepatocellular carcinoma. Biochemical and Biophysical Research Communications 434: 449–454.CrossRefPubMed
65.
Vanhooren, V., R.E. Vandenbroucke, S. Dewaele, E. Van Hamme, J.J. Haigh, T. Hochepied, et al. 2013. Mice overexpressing beta-1,4-galactosyltransferase I are resistant to TNF-induced inflammation and DSS-induced colitis. PLoS One 8: e79883.CrossRefPubMedPubMedCentral
66.
Parekh, R.B., A.G. Tse, R.A. Dwek, A.F. Williams, and T.W. Rademacher. 1987. Tissue-specific N-Glycosylation, site-specific oligosaccharide patterns and lentil lectin recognition of rat Thy-1. The EMBO Journal 6: 1233–1244.PubMedPubMedCentralCrossRef
67.
Schmieder, S., S. Lindenthal, and J. Ehrenfeld. 2001. Tissue-specific N-glycosylation of the ClC-3 chloride channel. Biochemical and Biophysical Research Communications 286: 635–640.CrossRefPubMed
Metadata
Title
β4GalT1 Mediates PPARγ N-Glycosylation to Attenuate Microglia Inflammatory Activation
Authors
Xiaojuan Liu
Aihong Li
Yuanyuan Ju
Wangrui Liu
Hui Shi
Renyue Hu
Zijian Zhou
Xiaolei Sun
Publication date
01-08-2018
Publisher
Springer US
Published in
Inflammation / Issue 4/2018
Print ISSN: 0360-3997
Electronic ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-018-0789-4

Other articles of this Issue 4/2018

Inflammation 4/2018 Go to the issue

ORIGINAL ARTICLE

Anti-inflammatory Drug Dexamethasone Treatment During the Remobilization Period Improves Range of Motion in a Rat Knee Model of Joint Contracture

ORIGINAL ARTICLE

Differential Effects of Brain Death on Rat Microcirculation and Intestinal Inflammation: Female Versus Male

ORIGINAL ARTICLE

SERMs Promote Anti-Inflammatory Signaling and Phenotype of CD14+ Cells

ORIGINAL ARTICLE

Protective Effects of Isoliquiritigenin on LPS-Induced Acute Lung Injury by Activating PPAR-γ

ORIGINAL ARTICLE

CpG-ODNs and Budesonide Act Synergistically to Improve Allergic Responses in Combined Allergic Rhinitis and Asthma Syndrome Induced by Chronic Exposure to Ovalbumin by Modulating the TSLP-DC-OX40L Axis

ORIGINAL ARTICLE

Large-Volume Crystalloid Fluid Is Associated with Increased Hyaluronan Shedding and Inflammation in a Canine Hemorrhagic Shock Model

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits